机构：[1]Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Med-X Center for Informatics, Sichuan University, Chengdu 610041, China.[3]Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[4]Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.四川大学华西医院
Infantile hemangioma (IH) is the most prevalent type of vascular tumor in infants. The pathophysiology of IH is unknown. The tissue structure and physiology of two-dimensional cell cultures differ greatly from those in vivo, and spontaneous regression often occurs during tumor formation in nude mice and has severely limited research into the pathogenesis and development of IH. By decellularizing porcine aorta, we attempted to obtain vascular-specific extracellular matrix as the bioink for fabricating micropattern arrays of varying diameters via microcontact printing. We then constructed IH-derived CD31+ hemangioma endothelial cell three-dimensional microtumor models. The vascular-specific and decellularized extracellular matrix was suitable for the growth of infantile hemangioma-derived endothelial cells. The KEGG signaling pathway analysis revealed enrichment primarily in stem cell pluripotency, RAS, and PI3KAkt compared to the two-dimensional cell model according to RNA sequencing. Propranolol, the first-line medication for IH, was also used to test the model's applicability. We also found that metformin had some impact on the condition. The three-dimensional microtumor models of CD31+ hemangioma endothelial cells were more robust and efficient experimental models for IH mechanistic exploration and drug screening.
基金：
National Natural Science Foundation of China (grant
number 82070640), the Key Project in the Science & Technology Program of Sichuan Province (grant
numbers 2022YFS0233, 2022YFS0225, 2022NSFSC1480, and 2019YFS0322); the Project of ‘0 to 1’ of
Sichuan University (grant number 2022SCUH0033); the Med-X Center for Informatics Funding
Project (YGJC004); the 1·3·5 Project for Disciplines of Excellence Clinical Research Incubation Project,
West China Hospital of Sichuan University (grant numbers ZYJC21060, ZYJC21014, 2020HXFH029,
2020HXFH048, and 2019HXFH056); and the Technological Innovation Project of Chengdu New
Industrial Technology Research Institute (grant number 2018-CY02-00046-GX).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区药学3 区药物化学
最新[2023]版：
大类|3 区医学
小类|3 区药物化学3 区药学
第一作者：
第一作者机构：[1]Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.[2]Med-X Center for Informatics, Sichuan University, Chengdu 610041, China.
共同第一作者：
通讯作者：
通讯机构：[1]Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.[2]Med-X Center for Informatics, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Li Yanan,Zhu Xinglong,Kong Meng,et al.Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening[J].Pharmaceuticals (Basel, Switzerland).2022,15(11):doi:10.3390/ph15111393.
APA：
Li Yanan,Zhu Xinglong,Kong Meng,Chen Siyuan,Bao Ji&Ji Yi.(2022).Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening.Pharmaceuticals (Basel, Switzerland),15,(11)
MLA：
Li Yanan,et al."Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening".Pharmaceuticals (Basel, Switzerland) 15..11(2022)
